Barker, Christopher A <br/><br/>
Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Aug 2010 
 - e426; author reply e427-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Comment 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2010.28.9488  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Agents--antagonists & inhibitors<br/>Clinical Trials as Topic<br/>Depsipeptides--pharmacology<br/>Disease-Free Survival<br/>Drug Interactions<br/>Histone Deacetylase Inhibitors--pharmacology<br/>Humans<br/>Hydroxamic Acids--pharmacology<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--pharmacology<br/>Lymphoma, Follicular--drug therapy<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Rituximab<br/>Vorinostat